SCHEMBL1895353

SCHEMBL1895353

CCOC(=O)c1c(-c2ccc(C)cc2)csc1NC(=O)c1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.78
KMT2A Q03164 6/20 0.78
PRNP P04156 2/20 0.78
ATM Q13315 1/20 0.78
L3MBTL1 Q9Y468 1/20 0.78
MAPT P10636 7/20 0.75
THRB P10828 5/20 0.67
TP53 P04637 3/20 0.67
PKM P14618 1/20 0.65
TNF P01375 1/20 0.64
NOD2 Q9HC29 1/20 0.64
NOD1 Q9Y239 1/20 0.64
ALDH1A1 P00352 2/20 0.61
KDM4E B2RXH2 1/20 0.61
HPGD P15428 1/20 0.61
PTPN1 P18031 2/20 0.59
LMNA P02545 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
ALOX12 P18054 1/20 0.59
POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1907181 0.88 MEN1 (1.00) MEN1KMT2APRNPATML3MBTL1
SCHEMBL21247167 0.83 LMNA (0.81) MEN1KMT2AMAPTTHRBTP53
SCHEMBL12314164 0.78 MEN1 (1.00) MEN1KMT2APRNPATML3MBTL1
SCHEMBL3931523 0.78 PTPN1 (0.78) MEN1KMT2AMAPTTHRBTP53
SCHEMBL14478927 0.76 TP53 (0.65) MEN1KMT2AL3MBTL1MAPTTHRB
SCHEMBL13962634 0.76 LMNA (0.72) MEN1KMT2AL3MBTL1MAPTTHRB
SCHEMBL3933219 0.76 LMNA (0.70) MEN1KMT2AMAPTTHRBTP53
SCHEMBL13837645 0.76 MAPT (0.76) MEN1KMT2AL3MBTL1MAPTPKM
SCHEMBL21247385 0.75 TP53 (0.72) MEN1KMT2AMAPTTHRBTP53
SCHEMBL5804278 0.74 MAPT (0.73) MEN1KMT2AL3MBTL1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130245025-A1 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2013-09-19 US disclosed
US-8394848-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2013-03-12 US disclosed
US-8383670-B2 Trisubstituted thiophenes that modulate intracellular calcium CALCIMEDICA, INC. (US) 2013-02-26 US disclosed
US-20110212970-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-09-01 US disclosed
US-20110136816-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-06-09 US disclosed
EP-2321303-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2011-05-18 EP disclosed
US-7906553-B2 Substituted thiophene modulators of intracellular calcium CALCIMEDICA, INC. (US) 2011-03-15 US disclosed
US-20100261725-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2010-10-14 US disclosed
WO-2010027875-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261725-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MEN1 2958/4885KMT2A 4706/4885PRNP 3058/4885
US-20110212970-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MEN1 2958/4885KMT2A 4706/4885PRNP 3058/4885
US-20130245025-A1 Compounds that modulate intracellular calcium ORAI1, SARAF, RYR2 MEN1 2958/4885KMT2A 4706/4885PRNP 3058/4885
US-20110136816-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MEN1 2958/4885KMT2A 4706/4885PRNP 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.